Studies on immune checkpoint inhibitor (ICI)-related potential neurological adverse events (pNAEs) in Korean lung cancer (LC) patients are scarce. We aimed to examine ICI prescription trends from 2018 to 2022, patient characteristics and factors associated with ICI prescription or concurrent pNAEs in LC. This observational, cross-sectional study of Korean LC patients investigated four ICIs (pembrolizumab, nivolumab, atezolizumab and durvalumab). The annual ICI prescription rate was calculated by dividing the number of LC patients prescribed ICIs with the total annual number of LC patients. Factors associated with ICI prescriptions or concurrent pNAEs were assessed. The annual ICI prescription rate increased from 3.29% to 9.74% (average: 6.20%). Higher Charlson Comorbidity Index (CCI) scores were associated with more ICI prescriptions (odds ratio [OR], 1.08; 95% confidence interval [CI], 1.07-1.08). Targeted therapy was associated with fewer prescriptions (OR: 0.45; 95% CI: 0.41-0.49). The anti-programmed cell death protein 1 (anti-PD-1) prescription rate was higher in patients with concurrent pNAEs than those without pNAEs (53.09% vs. 50.84%), and this was associated with higher pNAEs prevalence (OR: 1.10; 95% CI: 1.03-1.18). ICI prescription for LC has increased in Korea, CCI and anti-PD-1 increased pNAEs prevalence.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11654806 | PMC |
| http://dx.doi.org/10.1080/14796694.2024.2416378 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Can We Prevent Recurrent UTIs Without Antibiotics, in Both Those Who Do and Do Not Use Catheters? ICI-RS 2024.
Neurourol Urodyn
December 2024
Department of UroGynaecology, Norfolk & Norwich University Hospitals NHS Foundation Trust, Norwich, UK.
Aims: Urinary tract infections are one of the most common reasons for antibiotic prescription. The widespread use of antibiotic treatments contributes to the global health problem of antimicrobial resistance development. To slow down the progression of antimicrobial resistance, it is essential that we explore nonantibiotic preventive treatments for this common condition.
View Article and Find Full Text PDFPneumonitis after normofractionated radioimmunotherapy: a method for dosimetric evaluation.
Radiat Oncol
November 2024
Department of Radiation Oncology, School of Medicine and Klinikum rechts der Isar, Technical University of Munich (TUM), 81675, Munich, Germany.
Background: Post-Therapy-Pneumonitis (PTP) is a critical side effect of both, thoracic radio(chemo)therapy (R(C)T) and immune checkpoint inhibition (ICI). However, disease characteristics and patient-specific risk factors of PTP after combined R(C)T + ICI are less understood. Given that RT-triggered PTP is strongly dependent on the volume and dose of RT [1], driven by inflammatory mechanisms, we hypothesize that combination therapy of R(C)T with ICI influences the dose-volume-effect correlation for PTP.
View Article and Find Full Text PDFDeterminants of immune checkpoint inhibitor use and factors linked to neurological adverse events in Korean lung cancer.
Future Oncol
December 2024
College of Pharmacy, Ajou University, Suwon, Republic of Korea.
Studies on immune checkpoint inhibitor (ICI)-related potential neurological adverse events (pNAEs) in Korean lung cancer (LC) patients are scarce. We aimed to examine ICI prescription trends from 2018 to 2022, patient characteristics and factors associated with ICI prescription or concurrent pNAEs in LC. This observational, cross-sectional study of Korean LC patients investigated four ICIs (pembrolizumab, nivolumab, atezolizumab and durvalumab).
View Article and Find Full Text PDFTrends in the prescription of immune checkpoint inhibitors for non-small cell lung cancer in the Netherlands from 2016 to 2020, a national cancer registry analysis.
Transl Lung Cancer Res
September 2024
Unit of Oncological Epidemiology, Department of Epidemiology, Graduate School of Medical Sciences, University of Groningen, Groningen, The Netherlands.
Article Synopsis
- - Lung cancer remains the top cause of cancer deaths globally with a low 5-year survival rate, but the introduction of immune checkpoint inhibitors (ICIs) like nivolumab in 2015 has improved patient survival rates and treatment strategies for non-small cell lung cancer (NSCLC).
- - An analysis of the Netherlands Cancer Registry from 2016-2020 reveals a dramatic increase in ICI usage from 1.1% to 54.9% among first-line NSCLC patients, with trends indicating a shift away from chemotherapy, though survival rates varied and showed some decline in recent years.
- - The study highlights that the median overall survival (OS) was different based on treatment lines: first-line patients had a
Nivolumab-Induced Neuromyopathy: A Case Report.
Cureus
September 2024
Nephrology, Staten Island University Hospital, Staten Island, USA.
Nivolumab is an immune checkpoint inhibitor (ICI) that treats various malignancies. Although ICIs have proven efficacious, they can also have detrimental side effects. We present a case of nivolumab-induced quadriparesis mimicking Guillain-Barré syndrome in a patient with stage III squamous cell carcinoma (SCC) of the pharynx with a chronic tracheostomy, who presented after being found unconscious at home.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!